{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Viread&page=19",
    "query": {
      "intervention": "Viread",
      "page": 19
    },
    "page_size": 10
  },
  "pagination": {
    "page": 19,
    "page_size": 10,
    "total_count": 522,
    "total_pages": 53,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Viread&page=20&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Viread&page=18&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T09:44:12.491Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04442737",
      "title": "A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV-1"
      ],
      "interventions": [
        {
          "name": "D/C/F/TAF FDC",
          "type": "DRUG"
        },
        {
          "name": "TAF/FTC FDC",
          "type": "DRUG"
        },
        {
          "name": "INI Based Regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 103,
      "start_date": "2020-07-01",
      "completion_date": "2023-08-30",
      "has_results": true,
      "last_update_posted_date": "2025-03-30",
      "last_synced_at": "2026-11-15T09:44:12.491Z",
      "location_count": 34,
      "location_summary": "Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 28 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Ft. Pierce",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04442737"
    },
    {
      "nct_id": "NCT00677300",
      "title": "Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Raltegravir",
          "type": "DRUG"
        },
        {
          "name": "Darunavir",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        },
        {
          "name": "Tenofovir/Emtricitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dallas VA Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2009-01",
      "completion_date": "2012-12",
      "has_results": false,
      "last_update_posted_date": "2014-09-08",
      "last_synced_at": "2026-11-15T09:44:12.491Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00677300"
    },
    {
      "nct_id": "NCT01694407",
      "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "Tenofovir (TFV) Alone Vaginal Tablet",
          "type": "DRUG"
        },
        {
          "name": "Emtricitabine (FTC) Alone Vaginal Tablet",
          "type": "DRUG"
        },
        {
          "name": "TFV and FTC Combined Vaginal Tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo Vaginal Tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CONRAD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 48,
      "start_date": "2013-02",
      "completion_date": "2013-12",
      "has_results": false,
      "last_update_posted_date": "2015-04-03",
      "last_synced_at": "2026-11-15T09:44:12.491Z",
      "location_count": 2,
      "location_summary": "The Bronx, New York • Norfolk, Virginia",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01694407"
    },
    {
      "nct_id": "NCT02556333",
      "title": "Emtricitabine/Tenofovir Alafenamide as Salvage ART",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "FTC/TAF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "14 Years to 100 Years"
      },
      "enrollment_count": 1,
      "start_date": "2015-09-16",
      "completion_date": "2016-08-16",
      "has_results": true,
      "last_update_posted_date": "2017-11-14",
      "last_synced_at": "2026-11-15T09:44:12.491Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02556333"
    },
    {
      "nct_id": "NCT06630286",
      "title": "Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV-1-infection"
      ],
      "interventions": [
        {
          "name": "ISL/LEN",
          "type": "DRUG"
        },
        {
          "name": "B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "PTM B/F/TAF",
          "type": "DRUG"
        },
        {
          "name": "PTM ISL/LEN",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 609,
      "start_date": "2024-10-09",
      "completion_date": "2030-08",
      "has_results": false,
      "last_update_posted_date": "2026-04-30",
      "last_synced_at": "2026-11-15T09:44:12.491Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 50 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06630286"
    },
    {
      "nct_id": "NCT04454567",
      "title": "A Study Evaluating Treatment Intensification With ABI-H0731 in Participants With Chronic Hepatitis B Infection on Nucleos(t)Ide Reverse Transcriptase Inhibitors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "ABI-H0731",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "NrtI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Assembly Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2020-11-11",
      "completion_date": "2021-04-08",
      "has_results": true,
      "last_update_posted_date": "2022-10-20",
      "last_synced_at": "2026-11-15T09:44:12.491Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Pasadena, California • San Diego, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04454567"
    },
    {
      "nct_id": "NCT03549689",
      "title": "Effect of Reducing Nucleotide Exposure on Bone Health (ReNew)",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV/AIDS",
        "HIV-1-infection",
        "Osteopenia"
      ],
      "interventions": [
        {
          "name": "Dolutegravir (DTG) 50MG/lamivudine (3TC) 300MG FIXED DOSE COMBINATION (FDC)",
          "type": "DRUG"
        },
        {
          "name": "Current tenofovir alafenamide (TAF)-containing ART regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Philip Grant",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2019-08-01",
      "completion_date": "2021-07-01",
      "has_results": false,
      "last_update_posted_date": "2021-03-15",
      "last_synced_at": "2026-11-15T09:44:12.491Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03549689"
    },
    {
      "nct_id": "NCT03060785",
      "title": "Finding the Right Tenofovir/Emtricitabine Regimen for Pre-Exposure Prophylaxis (PrEP) in Transgender Women",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Prevention"
      ],
      "interventions": [
        {
          "name": "Tenofovir Disoproxil Fumarate/Emtricitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 16,
      "start_date": "2016-03-08",
      "completion_date": "2018-05-31",
      "has_results": false,
      "last_update_posted_date": "2018-07-18",
      "last_synced_at": "2026-11-15T09:44:12.491Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03060785"
    },
    {
      "nct_id": "NCT02006264",
      "title": "Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "TDF Intravaginal Ring",
          "type": "DRUG"
        },
        {
          "name": "Placebo Intravaginal Ring",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 30,
      "start_date": "2013-11-19",
      "completion_date": "2014-11-06",
      "has_results": true,
      "last_update_posted_date": "2018-08-28",
      "last_synced_at": "2026-11-15T09:44:12.491Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02006264"
    },
    {
      "nct_id": "NCT00458393",
      "title": "Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Prevention in Men",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "daily TDF/FTC",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 2499,
      "start_date": "2007-06",
      "completion_date": "2014-02",
      "has_results": true,
      "last_update_posted_date": "2021-11-02",
      "last_synced_at": "2026-11-15T09:44:12.491Z",
      "location_count": 3,
      "location_summary": "San Francisco, California • Chicago, Illinois • Boston, Massachusetts",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00458393"
    }
  ]
}